• Regulatory NewsRegulatory News

    EMA Reviews Safety of PAH Medicine Following 5 Deaths in France

    The European Medicines Agency (EMA) signaled Tuesday that doctors can continue to use Actelion Pharmaceuticals’ pulmonary arterial hypertension (PAH) medicine Uptravi (selexipag) while the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) evaluates its safety following the deaths of five patients taking the medicine in France. “Based on a preliminary review of available data, EMA advises that Uptravi may continue to be used, both in existing and new pat...